NET PROFITS UP AT SORIN BIOMEDICA
The biomedical arm of the Italian company Snia, Sorin Biomedica, ended 1992 with net profit of 30.6 billion lire ($195.8 million), compared with net profit in 1991 of 23.1 billion lire. This amounts to an increase of 32.5%, according to local reports.
The parent company Sorin Biomedica Spa, however, did not perform so well. Following capital losses from its shareholding portfolio, its net profit was more than halved to 5.9 billion lire ($3.8 million), from around 12.3 billion lire a year earlier.
The board is proposing shareholders a 140 lire dividend, which it says will be achieved by drawing 60 lire per share from the stock appreciation fund. Overall, the company will be distributing 20.4 billion lire, up from 13.8 billion lire in the previous year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze